Niagen Bioscience, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Niagen Bioscience, Inc.
2.34
−14.70%
vs ±27.5% implied · ×0.53
shaded = implied · ▲▼ = realized
Niagen Bioscience has 2 disclosed suppliers and 3 disclosed customers in SEC filings.
NoteCustomers that represented more than 10% of net sales during the year ended December 31, 2024 are presented in the table below as a percentage of net sales. Year Ended December 31, Major Customers 2024 A.S. Watson Group (1) 12.5 % Customer A 11.7 % (1) Customer was classified as a related party for part of the yea
| Year Ended December 31, | |
|---|---|
| Major Customers | 2024 |
| A.S. Watson Group (1) | 12.5% |
basisNAGE FY2025 revenue $129M
NAGE 10-Kaccession 0001386570-26-000013
SentenceUnder the Assignment Agreement, QUB assigned to us all of its interest in certain patent rights that had been previously jointly owned with, or licensed from, QUB.
NAGE 10-Kaccession 0001386570-26-000013
SentenceWe have entered into a long-term supply agreement with W.R. Grace & Co.-Conn. (Grace), pursuant to which Grace is our exclusive supplier of food-grade NRC that meets specified quality standards.
NAGE 10-Kaccession 0001386570-26-000013
SentencePursuant to the Supply Agreement, NHSc and its affiliates will exclusively purchase nicotinamide riboside chloride (NRCL) from the Company and NHSc and its affiliates will have the non-exclusive right to manufacture, market, distribute, and sell products using NRCL for human use in the (i) medical nutritional, (ii) functional food and beverage and (iii) multi-ingredient dietary supplements categories sold under one of the NHSc brands (the "Approved Products") world-wide, but excluding certain countries and ingredient combinations.
NAGE 10-Kaccession 0001386570-26-000013
Expected move
Inputsspot 2.33exp Nov 20ATM strike 2.5ATM straddle 0.53IV 110%